Genegraft

 

GENEGRAFT is a ‘bench to bedside’ project aims to find a durable and efficient treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) one of the most severe orphan diseases of the skin.

 

In Europe, Dystrophic Epidermolysis Bullosa (DEB) affects more affects approximately 30,000 individuals (prevalence of about 60/million) and approximately 400-500,000 people worldwide. The patients suffer since birth from skin blistering, and from severe local and systemic complications resulting in poor prognosis.

Current medical care protocols for RDEB patients are limited to palliative procedures to treat bullous lesions and severe complications of the disease (joint contractures, malnutrition, infections, sepsis and aggressive skin cancer). However, these treatments cannot prevent recurrent blistering arising from defective type VII collagen expression.

GENEGRAFT proposed to achieve a safe and efficient ex vivo gene therapy approach for a permanent treatment of RDEB using transplantation of a new investigational medicinal product.

 IMG 9798-comp

european flag blueyellow standard This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement contract N° HEALTH-F2-2011-261392 - started on March 1st 2011 and will last 5 years.

 

 

 

Back 


 

Welcome to Genegraft website

 

GENEGRAFT is a ‘bench to bedside’ project aims to find a durable and efficient treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB) one of the most severe orphan diseases of the skin.

 

In Europe, Dystrophic Epidermolysis Bullosa (DEB) affects more affects approximately 30,000 individuals (prevalence of about 60/million) and approximately 400-500,000 people worldwide. The patients suffer since birth from skin blistering, and from severe local and systemic complications resulting in poor prognosis.

Current medical care protocols for RDEB patients are limited to palliative procedures to treat bullous lesions and severe complications of the disease (joint contractures, malnutrition, infections, sepsis and aggressive skin cancer). However, these treatments cannot prevent recurrent blistering arising from defective type VII collagen expression.

GENEGRAFT proposed to achieve a safe and efficient ex vivo gene therapy approach for a permanent treatment of RDEB using transplantation of a new investigational medicinal product.

 

 

The GENEGRAFT project is a collaborative project funded by the European Union as part of the 7th framework programme. GENEGRAFT - contract N° HEALTH-F2-2011-261392 - started on March 1st 2011 and will last 5 years.

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

Patricia Joseph-Mathieu, BSc, MBA
European Project Manager
Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser. This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.inserm-transfert.fr

Genegraft is a research program. The content of this website is not intended to give medical diagnosis, treatment or medical advice.

Copyright:

All rights reserved.

This information may be freely used and copied for educational and other non-commercial purposes, provided that any reproduction of data be accompanied by an acknowledgement of GENEGRAFT as the source (© Genegraft ).
This does not apply to the pages and images with explicitly reserved reproduction right : © followed by the right owner and the year of first circulation. Reproduction of the latter requires prior authorization from the GENEGRAFT for the pages.

Privacy Policy

Inserm Transfert will not to reveal information obtained from users. Such information is confidential and will only be used with users consent.  

According to the Law n°78-17"Informatique et Libertés/software and freedoms" and its amendments, users have the right to access, modify, correct and delete any personal data collected when visiting the site. The users can exercise such rights with:

INSERM TRANSFERT

7 rue de Watt  

75013 Paris, FRANCE  

©2008 TARCC
Design & Programming: 
ML Com, France